Clinical Trial Update: A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 study comparing DFD-03 (tazarotene) 0.1% lotion to Tazorac 0.1% cream for acne vulgaris completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• DFD-03 (tazarotene) lotion, 0.1% (tazarotene)
• Tazorac (tazarotene) cream, 0.1% (tazarotene)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2020-08-17